Director/PDMR Shareholding

RNS Number : 9597B

Genedrive PLC

04 February 2020

 

genedrive plc

("genedrive" or the "Company")

Notification and public disclosure of transactions by persons discharging

managerial responsibilities and persons closely associated with them

genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces that today David Budd, Chief Executive Officer, acquired 43,330 ordinary shares of 1.5p each ("Ordinary Shares") in the Company at a price of 11.5p per share and Chris Yates, Non-Executive Director, acquired 25,000 Ordinary Shares at 11.56p per share.

Following these purchases, David Budd is interested in 188,710 Ordinary Shares, 0.5% of the issued share capital of the Company, and Chris Yates is interested in 41,304 Ordinary Shares, 0.1% of the issued share capital of the Company.

The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

1.	Details of the person discharging managerial responsibilities / person closely associated
a.	Name	1.    David Budd 2.    Chris Yates
2.	Reason for the notification
a.	Position/status	1.    Chief Executive Officer 2.    Non-Executive Director
a.	Initial notification /Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	genedrive plc
b.	LEI	213800ZYODIRZ87Y4K14
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the Financial instrument, type of instrument Identification code	Ordinary shares of 1.5 pence each GB00B1VKB244
b.	Nature of the transaction	Purchase
c.	Price(s) and volume(s)	Price(s) Volume(s) 1.    11.50p 2.    11.56p 1.    43,330 2.    25,000
d.	Aggregated information ·    Aggregated volume ·    Price	N/A
e.	Date of the transaction	2020-02-04
f.	Place of the transaction	London Stock Exchange, AIM

For further details please contact:

genedrive plc	[phone]
David Budd: CEO / Matthew Fowler: CFO
Peel Hunt LLP (Nominated Adviser and Joint Broker)	[phone]
James Steel / Oliver Jackson
Stanford Capital Partners Limited (Joint Broker)	[phone]
Patrick Claridge / John Howes
Walbrook PR Ltd (Media Relations & Investor Relations)	[phone] or [e-mail]
Paul McManus / Anna Dunphy	[phone] / [phone]

 

END

 

 

DSHEAKALEAFEEFA